FP268
3927MW
Dr.Ghizala begum c
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 3927MW | Dr.Ghizala begum c | ghizalabegummbbs@gmail.com | 8867438004 |
Community Ophthalmology
A Race for Relief: Alcaftadine Versus Bepotastine in VKC
ABSTARCT Background & Objectives: Vernal keratoconjunctivitis (VKC) is a recurrent allergic ocular surface disorder affecting children and adolescents. This study compared the efficacy and safety of alcaftadine 0.25% and bepotastine 1.5% in mild to moderate VKC. Methods: In this prospective comparative study, 112 patients were allocated to alcaftadine (n=56) or bepotastine (n=56). TOSS, hyperemia, and papillae were assessed at baseline and Weeks 1, 3, 5, and 8. Results: Both groups showed significant improvement over time (p<0.001). At Week 3, bepotastine produced significantly lower TOSS (0.59±0.50 vs 1.43±0.50), hyperemia (0.57±0.50 vs 1.27±0.45), and papillae scores (0.73±0.45 vs 1.41±0.50) than alcaftadine (all p<0.001). Outcomes were comparable by Week 5 and remained so at Week 8. No serious adverse events occurred. Conclusion: Both drugs were safe and effective, but bepotastine provided faster early clinical improvement.
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 1981 | Dr.Abhishek Kulkarni | abhi.5555@gmail.com | 8050155550 |
| 1884 | Dr.Sangeeta Vivek Patil | sangeetavivek.patil@gmail.com | 9535887750 |
| 2256 | Dr.Sana Hussaini | sanamustafahussaini@gmail.com | 9739786909 |